Pediatric Inflammatory Multisystem Syndrome (PIMS) - Potential role for cytokines such Is IL-6.

Area of Science:

• Pediatric immunology
• Infectious diseases
• Rheumatology

Background:

• COVID-19, caused by SARS-CoV-2, typically presents mildly in children.
• A growing number of children develop Pediatric Inflammatory Multisystem Syndrome (PIMS) post-COVID-19, resembling Kawasaki disease but with distinct laboratory findings.
• PIMS manifests 2-4 weeks after SARS-CoV-2 infection, presenting complex symptoms including gastrointestinal, cardiovascular, and mucocutaneous issues, potentially fatal without treatment.

Purpose of the Study:

• To review the role of the IL-6-IL-6R-STAT3 axis in the aetiopathogenesis of PIMS.
• To explore therapeutic strategies targeting the IL-6 pathway for severe PIMS cases.

Main Methods:

• Literature review summarizing current data on PIMS.
• Focus on the immunological mechanisms underlying PIMS.

Main Results:

• The IL-6-IL-6R-STAT3 axis plays a significant role in PIMS aetiopathogenesis.
• Immune hyperactivation is the proposed cause of PIMS.

Conclusions:

• The IL-6-IL-6R-STAT3 pathway is a key factor in PIMS development.
• Targeting IL-6 or its receptor presents a potential therapeutic approach for severe PIMS in children.